Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

The forkhead factor FOXL2: a novel tumor suppressor?

Benayoun BA, Kalfa N, Sultan C, Veitia RA.

Biochim Biophys Acta. 2010 Jan;1805(1):1-5. doi: 10.1016/j.bbcan.2009.09.002. Epub 2009 Sep 10. Review.

PMID:
19747961
2.

Functional exploration of the adult ovarian granulosa cell tumor-associated somatic FOXL2 mutation p.Cys134Trp (c.402C>G).

Benayoun BA, Caburet S, Dipietromaria A, Georges A, D'Haene B, Pandaranayaka PJ, L'Hôte D, Todeschini AL, Krishnaswamy S, Fellous M, De Baere E, Veitia RA.

PLoS One. 2010 Jan 20;5(1):e8789. doi: 10.1371/journal.pone.0008789.

3.

The transcription factor FOXL2: at the crossroads of ovarian physiology and pathology.

Caburet S, Georges A, L'Hôte D, Todeschini AL, Benayoun BA, Veitia RA.

Mol Cell Endocrinol. 2012 Jun 5;356(1-2):55-64. doi: 10.1016/j.mce.2011.06.019. Epub 2011 Jul 8. Review.

PMID:
21763750
4.

Adult ovarian granulosa cell tumor transcriptomics: prevalence of FOXL2 target genes misregulation gives insights into the pathogenic mechanism of the p.Cys134Trp somatic mutation.

Benayoun BA, Anttonen M, L'Hôte D, Bailly-Bechet M, Andersson N, Heikinheimo M, Veitia RA.

Oncogene. 2013 May 30;32(22):2739-46. doi: 10.1038/onc.2012.298. Epub 2012 Jul 16.

PMID:
22797072
5.

Transcription factor FOXL2 protects granulosa cells from stress and delays cell cycle: role of its regulation by the SIRT1 deacetylase.

Benayoun BA, Georges AB, L'Hôte D, Andersson N, Dipietromaria A, Todeschini AL, Caburet S, Bazin C, Anttonen M, Veitia RA.

Hum Mol Genet. 2011 May 1;20(9):1673-86. doi: 10.1093/hmg/ddr042. Epub 2011 Feb 2.

PMID:
21289058
6.

FOXL2: a central transcription factor of the ovary.

Georges A, Auguste A, Bessière L, Vanet A, Todeschini AL, Veitia RA.

J Mol Endocrinol. 2013 Dec 19;52(1):R17-33. doi: 10.1530/JME-13-0159. Print 2014 Feb. Review.

PMID:
24049064
7.

FOXL2 suppresses proliferation, invasion and promotes apoptosis of cervical cancer cells.

Liu XL, Meng YH, Wang JL, Yang BB, Zhang F, Tang SJ.

Int J Clin Exp Pathol. 2014 Mar 15;7(4):1534-43. eCollection 2014.

8.

Premature ovarian failure and forkhead transcription factor FOXL2: blepharophimosis-ptosis-epicanthus inversus syndrome and ovarian dysfunction.

De Baere E, Copelli S, Caburet S, Laissue P, Beysen D, Christin-Maitre S, Bouchard P, Veitia R, Fellous M.

Pediatr Endocrinol Rev. 2005 Jun;2(4):653-60. Review.

PMID:
16208278
9.

The mutations and potential targets of the forkhead transcription factor FOXL2.

Moumné L, Batista F, Benayoun BA, Nallathambi J, Fellous M, Sundaresan P, Veitia RA.

Mol Cell Endocrinol. 2008 Jan 30;282(1-2):2-11. Epub 2007 Nov 19. Review.

PMID:
18155828
10.

Mutations of the transcription factor FOXL2 gene in Chinese patients with blepharophimosis-ptosis-epicanthus inversus syndrome.

Li D, Zeng W, Tao J, Li S, Liang C, Chen X, Mu W, Wang X, Qin Y, Jie Y, Wei W.

Genet Test Mol Biomarkers. 2009 Apr;13(2):257-68. doi: 10.1089/gtmb.2008.0121.

PMID:
19371227
11.

The combination of polyalanine expansion mutation and a novel missense substitution in transcription factor FOXL2 leads to different ovarian phenotypes in blepharophimosis-ptosis-epicanthus inversus syndrome (BPES) patients.

Fan J, Zhou Y, Huang X, Zhang L, Yao Y, Song X, Chen J, Hu J, Ge S, Song H, Fan X.

Hum Reprod. 2012 Nov;27(11):3347-57. doi: 10.1093/humrep/des306. Epub 2012 Aug 27.

PMID:
22926839
12.

Spectrum of FOXL2 gene mutations in blepharophimosis-ptosis-epicanthus inversus (BPES) families demonstrates a genotype--phenotype correlation.

De Baere E, Dixon MJ, Small KW, Jabs EW, Leroy BP, Devriendt K, Gillerot Y, Mortier G, Meire F, Van Maldergem L, Courtens W, Hjalgrim H, Huang S, Liebaers I, Van Regemorter N, Touraine P, Praphanphoj V, Verloes A, Udar N, Yellore V, Chalukya M, Yelchits S, De Paepe A, Kuttenn F, Fellous M, Veitia R, Messiaen L.

Hum Mol Genet. 2001 Jul 15;10(15):1591-600.

PMID:
11468277
13.

Potential targets of FOXL2, a transcription factor involved in craniofacial and follicular development, identified by transcriptomics.

Batista F, Vaiman D, Dausset J, Fellous M, Veitia RA.

Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3330-5. Epub 2007 Feb 20.

14.

Novel FOXL2 mutations in two Chinese families with blepharophimosis-ptosis-epicanthus inversus syndrome.

Xue M, Zheng J, Zhou Q, Hejtmancik JF, Wang Y, Li S.

BMC Med Genet. 2015 Sep 1;16:73. doi: 10.1186/s12881-015-0217-7.

15.

FOXL2 gene mutations and blepharophimosis-ptosis-epicanthus inversus syndrome (BPES): a novel mutation detected in a Chinese family and a statistic model for summarizing previous reported records.

Xu Y, Lei H, Dong H, Zhang L, Qin Q, Gao J, Zou Y, Yan X.

Mutagenesis. 2009 Sep;24(5):447-53. doi: 10.1093/mutage/gep028. Epub 2009 Jul 10.

PMID:
19592504
16.

Foxl2 function in ovarian development.

Uhlenhaut NH, Treier M.

Mol Genet Metab. 2006 Jul;88(3):225-34. Epub 2006 May 2. Review.

PMID:
16647286
17.
18.

FOXL2 mutations in Taiwanese patients with blepharophimosis, ptosis, epicanthus inversus syndrome.

Lin WD, Chou IC, Lee NC, Wang CH, Hwu WL, Lin SP, Chao MC, Tsai Y, Tsai FJ.

Clin Chem Lab Med. 2010 Apr;48(4):485-8. doi: 10.1515/CCLM.2010.100.

PMID:
20184535
19.

Missense mutation outside the forkhead domain of FOXL2 causes a severe form of BPES type II.

Haghighi A, Verdin H, Haghighi-Kakhki H, Piri N, Gohari NS, De Baere E.

Mol Vis. 2012;18:211-8. Epub 2012 Jan 26.

20.

Discovery of novel protein partners of the transcription factor FOXL2 provides insights into its physiopathological roles.

L'Hôte D, Georges A, Todeschini AL, Kim JH, Benayoun BA, Bae J, Veitia RA.

Hum Mol Genet. 2012 Jul 15;21(14):3264-74. doi: 10.1093/hmg/dds170. Epub 2012 Apr 27.

PMID:
22544055

Supplemental Content

Support Center